vs
Side-by-side financial comparison of Organon & Co. (OGN) and SoFi Technologies, Inc. (SOFI). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.1B, roughly 1.3× SoFi Technologies, Inc.). SoFi Technologies, Inc. runs the higher net margin — 15.2% vs 10.0%, a 5.2% gap on every dollar of revenue. On growth, SoFi Technologies, Inc. posted the faster year-over-year revenue change (42.6% vs -3.5%). Over the past eight quarters, SoFi Technologies, Inc.'s revenue compounded faster (35.6% CAGR vs -4.7%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
SoFi Technologies, Inc. is an American financial technology company. Founded in 2011 by Stanford University students, it operates as a nationally chartered online bank and is a technology provider to other financial institutions. SoFi is the largest U.S. based online lender, and has 13.7 million customers as of 2025.
OGN vs SOFI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.1B |
| Net Profit | $146.0M | $166.7M |
| Gross Margin | 53.6% | — |
| Operating Margin | — | — |
| Net Margin | 10.0% | 15.2% |
| Revenue YoY | -3.5% | 42.6% |
| Net Profit YoY | 67.8% | 897.2% |
| EPS (diluted) | $0.55 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | $1.1B | ||
| Q4 25 | $1.5B | $1.0B | ||
| Q3 25 | $1.6B | $961.6M | ||
| Q2 25 | $1.6B | $854.9M | ||
| Q1 25 | $1.5B | $771.8M | ||
| Q4 24 | $1.6B | $734.1M | ||
| Q3 24 | $1.6B | $697.1M | ||
| Q2 24 | $1.6B | $598.6M |
| Q1 26 | $146.0M | $166.7M | ||
| Q4 25 | $-205.0M | $173.5M | ||
| Q3 25 | $160.0M | $139.4M | ||
| Q2 25 | $145.0M | $97.3M | ||
| Q1 25 | $87.0M | $71.1M | ||
| Q4 24 | $109.0M | $332.5M | ||
| Q3 24 | $359.0M | $60.7M | ||
| Q2 24 | $195.0M | $17.4M |
| Q1 26 | 53.6% | — | ||
| Q4 25 | 49.2% | 84.2% | ||
| Q3 25 | 53.5% | 83.2% | ||
| Q2 25 | 54.8% | 82.4% | ||
| Q1 25 | 55.6% | 82.4% | ||
| Q4 24 | 56.3% | 82.5% | ||
| Q3 24 | 58.3% | 82.3% | ||
| Q2 24 | 58.4% | 81.7% |
| Q1 26 | — | — | ||
| Q4 25 | -9.8% | 18.1% | ||
| Q3 25 | 15.2% | 15.4% | ||
| Q2 25 | 14.4% | 13.1% | ||
| Q1 25 | 6.7% | 10.3% | ||
| Q4 24 | 8.1% | 8.2% | ||
| Q3 24 | 13.1% | 9.2% | ||
| Q2 24 | 14.6% | 2.6% |
| Q1 26 | 10.0% | 15.2% | ||
| Q4 25 | -13.6% | 16.9% | ||
| Q3 25 | 10.0% | 14.5% | ||
| Q2 25 | 9.1% | 11.4% | ||
| Q1 25 | 5.8% | 9.2% | ||
| Q4 24 | 6.8% | 45.3% | ||
| Q3 24 | 22.7% | 8.7% | ||
| Q2 24 | 12.1% | 2.9% |
| Q1 26 | $0.55 | $0.12 | ||
| Q4 25 | $-0.78 | $0.14 | ||
| Q3 25 | $0.61 | $0.11 | ||
| Q2 25 | $0.56 | $0.08 | ||
| Q1 25 | $0.33 | $0.06 | ||
| Q4 24 | $0.42 | $0.31 | ||
| Q3 24 | $1.38 | $0.05 | ||
| Q2 24 | $0.75 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $3.4B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $10.8B |
| Total Assets | — | $53.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.4B | ||
| Q4 25 | $574.0M | $4.9B | ||
| Q3 25 | $672.0M | $3.2B | ||
| Q2 25 | $599.0M | $2.1B | ||
| Q1 25 | $547.0M | $2.1B | ||
| Q4 24 | $675.0M | $2.5B | ||
| Q3 24 | $763.0M | $2.4B | ||
| Q2 24 | $704.0M | $2.3B |
| Q1 26 | — | — | ||
| Q4 25 | $8.6B | — | ||
| Q3 25 | $8.8B | — | ||
| Q2 25 | $8.9B | — | ||
| Q1 25 | $9.0B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $8.7B | — | ||
| Q2 24 | $8.7B | — |
| Q1 26 | — | $10.8B | ||
| Q4 25 | $752.0M | $10.5B | ||
| Q3 25 | $906.0M | $8.8B | ||
| Q2 25 | $733.0M | $6.9B | ||
| Q1 25 | $542.0M | $6.7B | ||
| Q4 24 | $472.0M | $6.5B | ||
| Q3 24 | $493.0M | $6.1B | ||
| Q2 24 | $144.0M | $5.9B |
| Q1 26 | — | $53.7B | ||
| Q4 25 | $12.9B | $50.7B | ||
| Q3 25 | $13.6B | $45.3B | ||
| Q2 25 | $13.5B | $41.1B | ||
| Q1 25 | $13.2B | $37.7B | ||
| Q4 24 | $13.1B | $36.3B | ||
| Q3 24 | $12.8B | $34.4B | ||
| Q2 24 | $12.2B | $32.6B |
| Q1 26 | — | — | ||
| Q4 25 | 11.49× | — | ||
| Q3 25 | 9.74× | — | ||
| Q2 25 | 12.14× | — | ||
| Q1 25 | 16.52× | — | ||
| Q4 24 | 18.81× | — | ||
| Q3 24 | 17.75× | — | ||
| Q2 24 | 60.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
SOFI
| Loans and securitizations | $932.2M | 85% |
| Loan origination, sales, securitizations and servicing | $142.2M | 13% |
| Corporate borrowings | $10.7M | 1% |
| Securitizations and warehouses | $10.1M | 1% |
